What specific cost savings from the January 8, 2026 workforce reduction are detailed in recent SEC filings?

InflaRx N.V. (IFRX) announced a strategic restructuring on January 8, 2026, which includes an approximately 30% workforce reduction. This measure is intended to significantly reduce the company's cost structure and extend its cash runway to mid-2027.1

Key details from the SEC filing (Exhibit 99.1) include:

• Workforce Reduction: InflaRx is implementing an approximately 30% reduction in its global workforce.1
• Expected Cost Impact: The company anticipates that this will lead to a "significantly leaner cost structure, enabling substantial and sustained reductions in operating expenses."1
• One-Time Charges: InflaRx estimates a one-time charge of approximately $7 million associated with these restructuring activities.1 The majority of this charge is expected to be non-cash, related to the write-off of vilobelimab inventory, with a smaller portion covering personnel-related costs and the termination or modification of certain third-party contracts.1

While the filing indicates the strategic intent to achieve substantial and sustained reductions in operating expenses, it does not provide a specific, quantified annualized cost savings figure directly attributable to the workforce reduction itself in the provided text. The focus is on the one-time charges and the qualitative impact on the cost structure and cash runway.

For further analysis of InflaRx's financial health and operational efficiency, investors can utilize Fintel's platform to review historical SEC filings, institutional ownership trends, and analyst estimates for IFRX.